Could it be hypothesized that part of their plan to meet cashflow positive is to include the $5m payment due from Aktay in 2020? Or would that not count as 'revenue' in this context?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%